Jacobio Pharmaceuticals Group Co., Ltd. stock analysis
Want to see HK:1167 full AI Analyst Report?
Relatively low debt compared with equity gives Jacobio greater balance-sheet flexibility than a heavily leveraged biotech. This can preserve room to fund clinical development, absorb operating volatility, and pursue strategic opportunities, although the benefit is tempered by declining equity and continuing losses.
Strong gross margins in recent periods suggest that the underlying economics of successful revenue-generating activities can be attractive once sufficient income is achieved. This provides a possible foundation for future operating leverage, though current R&D and operating costs have prevented those margins from producing profitability.
A focused oncology and precision-medicine strategy gives Jacobio a clearly defined development direction and exposure to therapies aimed at specific molecular pathways. If clinical candidates advance successfully, this specialized pipeline could support partnering, licensing, and eventual commercialization opportunities.
A revenue decline of this magnitude weakens visibility into the company’s ability to generate recurring income and indicates that recent revenue performance is highly volatile. For a clinical-stage biotech, reduced income can make development spending more dependent on partnerships, milestones, or external financing.
Recurring operating and net losses show that Jacobio has not yet converted its research and development activities into sustainable earnings. Continued losses can constrain internal reinvestment, increase dependence on capital markets or partners, and make future profitability dependent on successful clinical and commercial execution.
Persistent negative operating and free cash flow indicate that the business is consuming rather than generating cash through its current operations. Higher recent burn increases funding sensitivity and may require continued use of external capital or balance-sheet resources to support clinical development and corporate activities.
Jacobio Pharmaceuticals Group Co., Ltd. ( ($HK:1167) ) has issued an announcement. Jacobio Pharmaceuticals reported interim results marked by continued progress in its oncology pipeline, led by glecirasib and sitneprotafib
Jacobio Pharmaceuticals Group Co., Ltd. ( ($HK:1167) ) just unveiled an announcement. Jacobio Pharmaceuticals Group Co., Ltd., a Cayman Islands-incorporated biopharmaceutical company listed in Hong Kong, specializes in targeted oncology
Jacobio Pharmaceuticals Group Co., Ltd. ( ($HK:1167) ) has provided an announcement. Jacobio Pharmaceuticals has dosed the first patient in China in a Phase Ib/III clinical trial of its orally
Jacobio Pharmaceuticals Group Co., Ltd. ( ($HK:1167) ) just unveiled an announcement. Jacobio Pharmaceuticals reported that all resolutions at its 5 June 2026 annual general meeting were approved by shareholders
An announcement from Jacobio Pharmaceuticals Group Co., Ltd. ( ($HK:1167) ) is now available. Jacobio Pharmaceuticals has been steadily repurchasing its own shares under an existing mandate, accumulating 7,47,800 treasury
An update from Jacobio Pharmaceuticals Group Co., Ltd. ( ($HK:1167) ) is now available. Jacobio Pharmaceuticals has received a US$100 million upfront payment from AstraZeneca under their license and collaboration
Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors, JAB-3312 and JAB-3068, which are being investigated for esophageal cancer. Also in development is JAB-8263, a small molecule designed to inhibit BET family proteins that regulate MYC transcription, aiming to treat a range of cancers, alongside JAB-21822, an oral small molecule specifically targeting the mutant KRAS G12C protein. Jacobio is further advancing JAB-BX102, a humanized inhibitory antibody against human CD73, intended for treating PD-1 resistant cancers. Other pipeline assets include JAB-6343, an inhibitor targeting fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma exhibiting FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, which targets a tumor metabolic pathway for solid tumor treatment; and JAB-BX300, a molecular antibody designed to target the RAS pathway for pancreatic and other solid tumors with KRAS mutations. The company maintains a strategic partnership with AbbVie Ireland Unlimited Company for the development and commercialization of SHP2 inhibitors. Established in 2015, Jacobio Pharmaceuticals is headquartered in Beijing, China.
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |
